


8. Bundesweite Onkologische Qualitätskonferenz 2020

Versorgungssituation beim Magen- und Ösophaguskarzinom



Richard Hummel, Lübeck





Magen- und Ösophaguskarzinom – Gemeldete Fälle pro Jahr



Magen- und Ösophaguskarzinom – Alter und Geschlecht I



Magen- und Ösophaguskarzinom – Alter und Geschlecht II




Magen- und Ösophaguskarzinom – Histologie Ösophaguskarzinom







Histology in esophagus

Histology in kardia

Histology in stomach




Magen- und Ösophaguskarzinom – Histologie Adenokarzinom




Magen- und Ösophaguskarzinom – Klinische Stadien bei Diagnose Ösophaguskarzinom

clinical stage over time



Adenokarzinom


clinical stage over time



Plattenepithelkarzinom




Magen- und Ösophaguskarzinom – Overall Survival nach Klinischem Stadium




Number at risk

Groups	0	12	24	36	48	60
I	568	298	187	124	81	62
II	1440	835	521	362	248	192
III	3143	1489	766	496	349	250
IV	2853	783	261	133	86	61




Number at risk

Groups	0	12	24	36	48	60
I	481	247	174	117	80	54
II	678	384	229	156	109	76
III	1358	706	379	213	144	107
IV	1639	470	143	58	31	20



Number at risk

Groups	0	12	24	36	48	60
I	2029	1137	863	669	524	404
II	2441	1372	863	573	392	257
III	1567	839	480	318	243	175
IV	8677	2101	672	317	182	124




Number at risk

Groups	0	12	24	36	48	60
I	514	290	215	151	110	85
II	665	343	222	146	105	65
III	1438	767	415	260	191	133
IV	2837	791	249	108	64	45



Magen- und Ösophaguskarzinom – Overall Survival




Number at risk

Groups	0	12	24	36	48	60
esophagus	4228	13849	7571	5067	3654	2758
kardia	6554	6928	3941	2649	1956	1487
stomach	8313	25638	16896	12580	9931	7911

Months after diagnosis


Magen- und Ösophaguskarzinom – Behandlung des fortgeschrittenen Tumorleidens I

Plattenepithelkarzinom
des Ösophagus




Magen- und Ösophaguskarzinom – Behandlung des fortgeschrittenen Tumorleidens II


SCC




ACA




Magen




Kardia



Magen- und Ösophaguskarzinom – Survival des fortgeschrittenen Tumorleidens I




Magen




Kardia



Magen- und Ösophaguskarzinom – Survival des fortgeschrittenen Tumorleidens II



Magen




Kardia




Magen- und Ösophaguskarzinom – Outlook

Magen uT2N0



Survival after Diagnosis



Kardia FLOT vs ECF

Fazit – Magen- und Ösophaguskarzinom

- Verschiebung Inzidenzen => **Kardiakarzinom / Adenokarzinom**
- Bei **Frauen** späterer Altersgipfel, **Alter** zunehmend
- Stadium 4 <50%, **Diagnose früher**
- Adenokarzinome mit unterschiedlichen **histologischen Subtypen**
- Zunehmend **neoadjuvante / perioperative** Therapie-Konzepte mit besserem Outcome
- Adenokarzinom: **perioperative Therapie überlegen**
- Großes **Potential der Registerdaten**



8. Bundesweite Onkologische Qualitätskonferenz 2020

Versorgungssituation beim Magen- und Ösophaguskarzinom

Richard Hummel, Lübeck

